Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2011-07-05
2011-07-05
Nguyen, Quang (Department: 1633)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S456000, C435S320100
Reexamination Certificate
active
07972856
ABSTRACT:
This invention provides methods for obtaining targeted gene modification in vertebrate cells using parvoviral vectors, including adeno-associated virus (AAV). The parvoviral vectors used in the methods of the invention are capable of targeting a specific genetic modification to a preselected target locus in a cellular genome by homologous pairing.
REFERENCES:
patent: 5340740 (1994-08-01), Petitte et al.
patent: 5455169 (1995-10-01), Mullan
patent: 5468629 (1995-11-01), Calhoun
patent: 5585254 (1996-12-01), Maxwell et al.
patent: 5602307 (1997-02-01), Beaudet et al.
patent: 5604090 (1997-02-01), Alexander et al.
patent: 5614396 (1997-03-01), Bradley et al.
patent: 5631153 (1997-05-01), Capecchi et al.
patent: 5763240 (1998-06-01), Zarling et al.
patent: 5773289 (1998-06-01), Samulski et al.
patent: 5801030 (1998-09-01), McVey et al.
patent: 6147276 (2000-11-01), Campbell et al.
patent: 6200806 (2001-03-01), Thomson
patent: 6271436 (2001-08-01), Piedrahita et al.
patent: 6528313 (2003-03-01), Le Mouellic et al.
patent: 6528314 (2003-03-01), Le Mouellic et al.
patent: 6638768 (2003-10-01), Le Mouellic et al.
patent: 2001/0051611 (2001-12-01), Srivastava et al.
patent: 2004/0203153 (2004-10-01), Le Mouellic et al.
patent: 2004/0250301 (2004-12-01), Mouellic et al.
patent: 90/11354 (1990-10-01), None
patent: WO 93/22426 (1993-11-01), None
patent: WO 94/28884 (1994-11-01), None
patent: WO 97/47758 (1997-12-01), None
patent: 98/48005 (1998-10-01), None
patent: 00/24917 (2000-05-01), None
patent: 02/091866 (2002-11-01), None
Verma et al. Gene therapy: Twenty-First Century Medicine. Annu. Rev. Biochem. 74:711-738, 2005.
Liu et al. Targeted correction of single-base-pair mutations with adeno-associated vius vectors under nonselective conditions. J. Virol.78:4165-4175, 2004.
Porter, A.C.G. Correcting a deficiency. Mol. Therapy 3:423-424, 2001.
Hirata et al. Design and packaging of adeno-assoicated virus gene targeting vectors. J. Virol. 74:4612-4620,2000.
Wang et al. Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombiant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions. J. Virol. 70:1668-1677, 1996.
Aguzzi et al., “Transgenic and Knock-out Mice: Models of Neurological Disease,”Brain Path. 4:3-20 (1994).
Bernstein, “Have you used an adeno vector . . . lately?”Nature Genetics, 18:305-306 (Apr. 1998).
Bohenzky et al., “Sequence and Symmetry Requirements within the Internal Palindromic Sequences of the Adeno-Associated Virus Terminal Repeat,”Virology166: 316-27 (1988).
Bradley, et al., “Modifying the Mouse: Design and Desire,”Biotechnology10: 534-539 (1992).
Chiorini et al., “Cloning of Adeno-Associated Virus Type 4 (AAV4) and Generation of Recombinant AAV4 Particles,”J. Virol.71: 6823-6833 (Sep. 1997).
Christensen et al., “A Novel Cellular Site-Specific DNA-Binding Protein Cooperates with the Viral NS1 Polypeptide to Initiate Parvovirus DNA Replication,”J. Virol.71: 1405-1416 (Feb. 1997).
Corsini et al., “Symmetric-Strand Packaging of Recombinant Parvovirus LuIII Genomes That Retain Only the Terminal Regions,”J. Virol.69: 2692-2696 (Apr. 1995).
Costello et al., “The Mismatched Nucleotides in the 5'-Terminal Hairpin of Minute Virus of Mice Are Required for Efficient Viral DNA Replication,”J. Virol.69: 7489-7496 (Dec. 1995).
Doetschman et al., “Establishment of Hamster Blastocyst-Derived Embryonic Stem (ES) Cells,”Dev. Biol.127:224-227 (1988).
DuPont et al., “Use of an Autonomous Parvovirus Vector for Selective Transfer of a Foreign Gene into Transformed Human Cells of Different Tissue Origins and Its Expression Therein,”J. Virol.68: 1397-1406 (Mar. 1994).
Flotte and Carter, “Adeno-associated virus vectors for gene therapy,”Gene Therapy2: 357-362 (1995).
Graves and Moreadith, “Derivation and Characterization of Putative Pluripotential Embryonic Stem Cells From Preimplantation Rabbit Embryos,”Mol. Reprod. Dev.36:424-433 (1993).
Hong et al., “Production of medakafish chimeras from a stable embryonic stem cell line,”Proc. Natl. Acad. Sci. USA95:3679-3684 (1998).
Iannaccone et al., “Pluripotent Embryonic Stem Cells from the Rat Are Capable of Producing Chimeras,”Dev. Biol. 163:288-292 (1994).
Inoue, et al., “High-Fidelity Correction of Mutations at Multiple Chromosomal Positions by Adeno-Associated Virus Vectors,”J. Virol.73(9): 7376-7380 (Sep. 1999).
Kearns et al., “Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line,”Gene Therapy3: 748-755 (1996).
Mitani, et al., “Gene Targeting in Mouse Embryonic Stem Cells with an Adenoviral Vector,”Somatic Cell and Molecular Genetics, 21(4): 221-231 (1995).
Muramatsu et al., “Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3,”Virology221: 208-17 (Jul. 1, 1996) (abstract only).
Russell, et al., “Human Gene Targeting by Viral Vectors,”Nature Genetics, 18:325-330 (Apr. 1998).
Russell et al., “Transformation-Dependent Expression of Interleukin Genes Delivered by a Recombinant Parvovirus,”J. Virol. 66: 2821-2828 (May 1992).
Schoonjans et al., “Pluripotential Rabbit Embryonic Stem (ES) Cells Are Capable of Forming Overt Coat Color Chimeras Following Injection Into Blastocysts,”Mol. Reprod. Dev.45:439-43 (1996).
Sukoyan et al., “Isolation and Cultivation of Blastocyst-Derived Stem Cell Lines from American Mink (Mustela vison),”Mol. Reprod. Dev.33:418-31 (1992).
Thomson et al., “Isolation of a primate embryonic stem cell line,”Proc. Natl. Acad. Sci. USA92:7844-7848 (Aug. 1995).
Wakamatsu & Ozato, “Establishment of a pluripotent cell line derived from a medaka (Oryzias latipes) blastula embryo,”Mol. Mar. Bio. Biotechnol.3:185-91 (1994).
Wang and Srivastava, “A Novel Terminus Resolution-Like Site in the Adeno-Associated Virus Type 2 Genome,”J. Virol.71: 1140-1146 (Feb. 1997).
Wang et al., “Adeno-Associated Virus Type 2 DNA Replication In Vivo: Mutation Analyses of the D Sequence in Viral Inverted Terminal Repeats,”J. Virol. 71: 3077-3082 (Apr. 1997).
Ward and Berns, “Short Communication: Minimum Origin Requirements for Linear Duplex AAV DNA Replication in Vitro,”Virology209:692-05 (1995).
Weitzman et al., “Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA,”Proc. Natl. Acad. Sci. USA91:5808-5812 (Jun. 1994).
Wheeler, “Development and Validation of Swine Embryonic Stem Cells: a Review,”Reprod. Fertil. Dev. 6:563-68 (1994).
Xiao et al., “A Novel 165-Base-Pair Terminal Repeat Sequence Is the SolecisRequirement for the Adeno-Associated Virus Life Cycle,”J. Virol.71: 941-948 (Feb. 1997).
Yanez, et al., “Therapeutic Gene Targeting,”Gene Therapy, 5:149-159 (Feb. 1998).
Luo, F., et al. “Adeno-associated virus 2-mediated transfer and functional expression of a gene encoding the human granulocyte-macrophage colony-stimulating factor,” Blood, Journal of the American Society of Hematology (1993) Abstract No. 1196.
Zhou, S.Z., et al. “Adeno-associated virus 2-mediated gene transfer in hematopoietic progenitor cells in human umbilical cord blood,” Blood, Journal of the American Society of Hematology (1993) Abstract No. 1197.
Wursthorn, et al. “Liver Directed AAV-Mediated Homologous Recombination is Independent of Serotype,” American Society of Gene Therapy Meeting Abstracts (2007), Abstract No. 840.
Wursthorn, et al. “In Vivo Correction of a Metabolic Liver Disease by AAV8-Mediated Homologous Recombination,” American Society of Gene Therapy Meeting Abstracts (2007), Abstract N
Hirata Roli K.
Russell David W.
FitzGerald Mark J.
Nguyen Quang
Nixon & Peabody LLP
The University of Washington
LandOfFree
Targeted gene modification by parvoviral vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted gene modification by parvoviral vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted gene modification by parvoviral vectors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2701762